Sema4 Signal Hereditary Cancer offers a broad range of targeted panels

 

With a 14-21 day turnaround time, our germline testing panels can help providers quickly understand a patient’s hereditary cancer risk and develop appropriate clinical care strategies.

All of our panels are run on medical exome data from our Sema4 Traversa NGS-based platform, allowing us to introduce additional genes when new supporting evidence is published. We also provide clinical biobanking as standard to enable future testing.


 

Universal Panel (112 genes)*

The most comprehensive hereditary cancer testing panel available, providing insights on 112 genes associated with known or possible increased risk of hereditary cancer across the major organ systems

 

Sub-panels (16 panels) – Including:

      • Comprehensive Panel (72 genes): Evaluates multiple hereditary cancer conditions
      • High Prevalence Panel (36 genes): Maximizes diagnostic yield for individuals with personal and/or family history of cancer
      • Organ-specific panels: Including breast, breast/gynecological, colorectal, pancreatic, prostate, melanoma, endocrine, brain/neurological, and renal/urinary panels
      • STAT Breast Guidelines panel: 10 day turnaround time
      • Syndrome-specific panels: Including hereditary breast and ovarian cancer (HBOC) and Lynch syndrome

 

Customizable panel options

 

 

Single gene testing

 

* The Universal Panel is best suited to research studies. For highest clinical utility, and lower VUS rate, providers should choose the Comprehensive Panel.

 

View Panel Guide

 

Connect with us today

Feel free to call us at 833-486-6260 or fill out the form below and we’ll schedule a time to discuss your needs.